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adherence (adjusted OR: 2.67; CI: 1.38–5.15) at t 1 . Depression 
(adjusted regression coefficient:   = 0.96; p = 0.001) and sub-
threshold depression (  = 1.01; p  ! 0.001) at t 0 also predicted 
increased problems with diabetes-related health behavior 
at t 1 . Adjusted ORs for poor glycemic control (HbA 1c  6 7%) at 
t 1 were also increased for patients with baseline depression 
(2.01; CI: 1.10–3.69). However, problems with medication ad-
herence as well as problems with diabetes-related health 
 behavior at t 0 did not predict poor glycemic control at t 1 . 
 Conclusions: In a prospective representative study of pa-
tients with type 2 diabetes, baseline depression predict-
ed problems with medication adherence, problems with 
health-related behaviors, and unsatisfactory glycemic con-
trol at  follow-up.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 There is a two- to three-fold risk of depression in pa-
tients with type 2 diabetes, suggesting that depression is 
strongly related to this disease  [1] . Comorbid depression 
in diabetes was thereby found to be associated with in-
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 Abstract 
 Background: Findings are inconsistent regarding the de-
gree to which depression may exert a negative impact on 
glycemic control in patients with type 2 diabetes. We there-
fore aimed to examine the longitudinal relationship be-
tween depression, behavioral factors, and glycemic control. 
 Methods: In a prospective component of a nationally repre-
sentative sample, 866 patients with type 2 diabetes aged 
 6 18 years completed a standardized assessment including 
a laboratory screening, questionnaires, and diagnostic mea-
sures. Subsequent to baseline (t 0 ), patients were tracked 
over a period of 12 months (t 1 ). Depression was assessed ac-
cording to DSM-IV and ICD-10 criteria. Glycemic control was 
determined by levels of glycosylated hemoglobin (HbA 1c ); a 
level of  6 7% was judged as unsatisfactory. Regression anal-
yses were performed to analyze the prospective relationship 
between depression, medication adherence, diabetes-relat-
ed health behavior, and HbA 1c .  Results: Patients with de-
pression at t 0 revealed increased rates of medication non-
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creased instances and severities of medical complications 
 [2] , poorer overall health status  [3] , more absences from 
work  [4] , higher health care costs  [5] , and increased mor-
tality  [6] , as opposed to diabetes without depression.
 Recent research suggests a bidirectional association 
between diabetes and depression  [7] . However, the bio-
logical and behavioral mechanisms of this association re-
main unclear  [8] . In addition to the direct negative phys-
iological effects on glucose metabolism (activation of the 
neuroendocrine and inflammatory responses  [9] ) and 
behavioral risk factors such as obesity-promoting health 
behaviors (e.g. physical inactivity, hypercaloric diets),
depression produces an especially poor adherence to a 
variety of self-care responsibilities (e.g. medications or 
modification of health behaviors), which is considered to 
be related to the state of glycemic control  [10] .
 High glycosylated hemoglobin (HbA 1c ) is an index of 
long-term glycemic control and an independent predic-
tor of diabetes. High levels of HbA 1c are associated with 
an increased risk of medical complications, mortality, 
and poor quality of life in patients with type 2 diabetes 
 [11] . However, previous results regarding the association 
of depression and HbA 1c in patients with type 2 diabetes 
are inconsistent  [12–14] , which is surprising in light of
the strong association between depression and diabetes. 
Moreover, in the field of primary care, these studies have 
been cross-sectional.
 Given these inconsistent results and the lack of pro-
spective examinations of the effect of depression on 
HbA 1c and relevant behavioral mechanisms (adherence 
to medications and health behaviors) linking these asso-
ciations, we used a nationally representative sample of 
primary care patients with type 2 diabetes to investigate: 
(1) the effects of depression on adherence to medical rec-
ommendations (concerning medication and health be-
havior), and (2) the effects of depression and adherence 
to medical recommendations (concerning medication 
and health behavior) on HbA 1c in primary care patients 
with type 2 diabetes over a 12-month follow-up period.
 Patients and Methods 
 Sample 
 Analyses were based on the DETECT (Diabetes Cardiovascu-
lar Risk Evaluation: Targets and Essential Data for Commitment 
of Treatment) study, which is a cross-sectional clinical-epidemio-
logical study with a prospective-longitudinal component in pri-
mary care in Germany. Data collection was performed between 
September 2003 and December 2004. A complete description of 
the study methodology and sampling has been published else-
where  [15] . 
 In brief, the DETECT study used a random subsample of 7,519 
patients of the core survey, which consisted of 55,518 unselected 
consecutive patients (aged  6 18 years) attending 3,188 primary 
care settings at baseline (t 0 ). It utilized a standardized assessment, 
including questionnaires for patients and physicians, and an ex-
tensive laboratory screening program with follow-up (t 1 ) after 12 
months. At t 1 , data from 6,627 (93.1%) patients were collected, in-
cluding 866 patients attending 466 different primary care settings 
who had been diagnosed with type 2 diabetes and had a valid 
score for depression.
 In the later analyses, the data were weighted to adjust for the 
regional distribution of general practitioners and internists to ob-
tain a representative sample of German primary care patients. 
The study sample of doctors can therefore be regarded as nation-
ally representative in terms of regional distribution, age, years of 
experience, specialty orientation, and patient load per day  [15] . 
The longitudinally investigated cohort was additionally adjusted 
to the morbidity status, age, and gender distribution of the main 
study. Moreover, there were no noteworthy differences in the 
characteristics of those patients analyzed only at baseline and the 
subsample followed up for 1 year  [15] . The 866 patients for whom 
a valid score for depression was available did not differ from the 
917 patients diagnosed with type 2 diabetes with regard to so-
ciodemographic or clinical variables. Therefore, the patient sam-
ple can also be regarded as representative of primary care settings 
in Germany  [15] .
 The study was approved by the local ethics committee of the 
Technical University Dresden (AZ: EK149092003; 16.09.2003).
 Assessment of Depression 
 The Depression Screening Questionnaire (DSQ) developed by 
Wittchen and Perkonigg  [16] is a well-established and frequently 
used instrument in large-scale studies in primary care  [17] . This 
self-report measure consists of 10 items with a 3-point scale with 
0 (never) through 1 (on some days) to 2 (on the majority of days) 
referring to the preceding 2 weeks. The diagnosis of depression 
can be made according to the ICD-10 criteria: at least 3 questions 
must be answered with ‘on the majority of days’ and the total score 
must be  1 7. The DSQ has a high internal consistency (Cronbach’s 
  = 0.83  [18] ), and the 1-week test-retest reliability found a   value 
of 0.82  [16] . The validity of the diagnosis of major depression is 
very high compared to the Composite International Diagnostic 
Interview  [19] :   = 0.89 for DSM-IV and   = 0.84 for ICD-10  [16] . 
In order to account for recent findings showing that subthreshold 
levels of depression also have a negative impact on health out-
comes in patients with type 2 diabetes  [20] , the calculated total 
scores were grouped into 3 categories: 0–4 points indicated no 
depression, 5–7 points indicated subthreshold depression, and  1 7 
points indicated depression. The cut-off of  ^  4 points was chosen 
for patients whose depressive symptomatology is not sufficient for 
the subthreshold category, taking into account 4 ‘somatic’ items 
that diabetic patients might experience due to resulting physical 
limitations (psychomotor retardation, sleep disturbance, loss of 
sexual desire, loss of appetite or weight loss).
 Assessment of Adherence 
 Medication nonadherence was assessed by responses to the 
question ‘How often did you have problems taking your medica-
tions as prescribed by the physician?’ based on a 4-level response 
scale (almost never/rarely/often/always) during the last 4 weeks. 
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Due to skewed data, the values were split into 2 categories: ‘near-
ly never’ versus ‘rarely/often/always’. Nonadherence with health 
behavior during the preceding 4 weeks was assessed by 5 items 
covering the frequency of problems with diet (2 items: healthy diet 
plans, weight control/reduction), stopping smoking, alcohol con-
sumption, and adequate physical activity, with 4 response possi-
bilities (never/rarely/often/almost daily). The values were added 
to a total score. Both assessments (adherence to medication/
health behaviors) have high face validity as they directly capture 
observable behavior patterns.
 Assessment of Diabetes and HbA 1c 
 Type 2 diabetes was assumed when the diagnosis was rated as 
‘definite’ (vs. ‘suspected’ or ‘no’) in the questionnaire answered 
by the physicians.  HbA 1c values were used as an indicator of gly-
cemic control. The general goal in the treatment of diabetes is a 
HbA 1c of  ! 7%  [21] . Therefore, HbA 1c values were classified as 
 6 7% (unsatisfactory glycemic control) and as  ! 7% (good glyce-
mic control).
 Statistical Analysis 
  2 or t tests were used to test for differences between type 2 
diabetes patients with various levels of depression.
 Logistic regression was used to analyze the effects of depres-
sion on problems with medication adherence and glycemic con-
trol. Linear regression models were employed to investigate the 
influence of depression on problems with health behavior. The 
odds ratios (ORs) and the regression coefficients (  ) were calcu-
lated with 95% CI. All models were adjusted for gender, age, mar-
ital and employment status, education, physical activity, BMI, 
smoking, drinking, duration of diabetes, and type of diabetes 
treatment. 
 Adjustments were also made to account for the stratified sam-
pling design and the resulting possibility of clustered observa-
tions: patients may be clustered in primary care units so that cor-
relations within these units can be assumed. Therefore, we calcu-
lated CIs for all regression analyses applying the Huber-White 
sandwich method  [22] .
 Power calculations (  2 test of trend in proportions based on 
the logistic model) revealed that given a sample size of 866 (  = 
0.05, two-sided), an OR of 2 for poor glycemic control is detectable 
with a power of 91%. For all analyses, the level of significance was 
set at p  ! 0.05. We employed the statistical package STATA 9.1.
 Results 
 For the prospective cohort study, the sociodemo-
graphic, behavioral, and clinical characteristics of the 
type 2 diabetes patients with no depression, subthreshold 
depression, or depression are compared in  table 1 . A total 
of 179 patients (20.7%) had subthreshold depression, and 
102 (11.7%) of the 866 patients suffered from depression. 
Compared to patients with no depression, patients with 
depression as well as patients with subthreshold depres-
sion were more frequently women with fewer weekly 
physical activities. Furthermore, patients with depres-
sion were younger, more likely to be smokers, less likely 
to drink alcohol, and were more often treated with insu-
lin compared to patients with no depression. Patients 
with depression were also younger and more likely to be 
smokers than patients with subthreshold depression. 
 Association of Depression, Medication Adherence, 
and Health Behavior at Baseline 
 At baseline, when adjusting for the covariates listed in 
 table 1 , patients with depression exhibited a higher risk 
(OR = 4.45; CI: 2.52–7.84; p  ! 0.001) of problems with 
medication adherence. Unfavorable health behavior was 
associated with subthreshold depression (  = 0.68; CI: 
0.29–1.08) and depression (  = 1.47; CI: 0.96–1.98; R 2 = 
0.41) at baseline. Having subthreshold depression was not 
associated with glycemic control at baseline. However, 
among those who had depression, the odds of problems 
with glycemic control at baseline were elevated (OR = 
1.71; CI: 1.01–2.90; p  ! 0.05). There were no associations 
between glycemic control and having problems with 
medication adherence or health behavior.
 Prediction of Glycemic Control, Medication 
Adherence, and Health Behavior 
 The prospective association between depression (t 0 ) 
and medication adherence and health behavior at follow-
up (t 1 )   is shown in  table 2 . Having subthreshold depres-
sion (t 0 ) is not associated with medication adherence 
problems at t 1 . However, among those who had depres-
sion, the odds of problems with medication adherence 
(adjusted for all covariates listed in  table 1 ) are elevated at 
t 1 (OR = 2.67; CI: 1.38–5.15; p = 0.003).  Table 2 also shows 
the crude and adjusted standardized regression coeffi-
cients for the association of depression (t 0 ) and problems 
with health behavior (t 1 ). In the adjusted model, having 
more problems with health behavior is associated with 
harboring subthreshold depression (  = 1.01; CI: 0.62–
1.40) and depression (  = 0.96; CI: 0.40–1.52; R 2 = 0.30) 
at baseline.
 The association between depression (t 0 ) and HbA 1c at 
t 1 is also shown in  table 2 . Having subthreshold depres-
sion (t 0 ) is not associated with glycemic control at t 1 . 
However, among those who were classified as depressed, 
the adjusted odds of problems with glycemic control are 
elevated at t 1 (OR = 2.01; CI: 1.10–3.69; p = 0.023). These 
analyses were also run separately for the association of 
medication adherence and health behavior (t 0 ) on glyce-
mic control at t 1 . After adjusting for the covariates, there 
are no significant associations between problems with 
medication adherence and health behavior (t 0 ) and prob-
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Table 1. Sociodemographic and clinical baseline characteristics of primary care patients by severity of depres-
sion (n = 866)
Variables No depression 
(n = 585)
Subthreshold
depression (n = 179)
Depression
(n = 102)
Female gender 266 (45.5) 100 (55.6)a 57 (55.9)a
Age, years 66.889.7 66.8810.0 63.5811.9 b, d
Years of education 9.281.9 9.281.7 9.281.8
Marital status
Single 24 (4.2) 10 (5.7) 6 (5.9)
Married 400 (69.6) 110 (62.5) 67 (66.3)
Divorced/widowed 151 (26.3) 56 (31.8) 28 (27.7)
Retired/unemployed/housewife 480 (82.9) 161 (90.4)a 90 (89.1)
Smoking c, d
Nonsmoker 463 (87.4) 147 (89.1) 78 (83.0)
Smoker 67 (12.6) 18 (10.9) 16 (17.0)
Amount of drinking c
Less than 2 times a month 267 (48.5) 94 (54.7) 68 (68.7)
Less than 2 times a week 111 (20.1) 37 (21.5) 14 (14.1)
3 or more times a week 137 (31.4) 41 (23.8) 17 (17.2)
BMI 29.484.7 30.185.1 30.585.8
Weekly physical activities <2 h 161 (30.1) 75 (46.3)c 41 (47.7)c
Duration of diabetes, years 7.686.7 8.687.7 8.487.4
Diabetes treatment a
None or diet 169 (28.9) 46 (25.6) 29 (28.7)
Oral hypoglycemic 352 (60.2) 104 (57.8) 51 (50.5)
Insulin or insulin + oral hypoglycemic 64 (10.9) 30 (16.7) 21 (20.8)
Data are presented as means 8 SD or number of patients with percentages in parentheses. 
a p < 0.05, b p < 0.01, c p < 0.001 vs. no depression, d p < 0.01 vs. subthreshold depression.
Table 2. OR for problems with medication adherence and glycemic control, and standardized regression coefficients () for problems 
with health behavior
Problems with medication adherence (t1) Problems with health behavior (t1) Problems with glycemic control1 (t1)
OR crude p OR adjusted2 p  crude p  adjusted2 p OR crude p OR adjusted2 p
No depression (t0) ref. ref. ref. ref. ref. ref.
Subthreshold
depression (t0)
1.4
(1.0–2.2)
0.14 1.2
(0.7–2.1)
0.43 1.1
(0.7–1.6)
<0.001 1.0
(0.6–1.4)
<0.001 0.9
(0.6–1.3)
0.65 0.7
(0.4–1.1)
0.17
Depression (t0) 2.9
(1.7–4.8)
<0.001 2.7
(1.4–5.1)
0.003 1.3
(0.7–1.9)
<0.001 1.0
(0.4–1.5)
0.001 2.1
(1.4–3.2)
<0.001 2.0
(1.1–3.7)
0.02
Problems with medica-
tion adherence (t0)
1.4
(1.0–2.1)
0.07 1.3
(0.9–2.0)
0.21
Problems with
health behavior (t0)
1.0
(1.0–1.1)
0.18 1.0
(0.9–1.1)
0.84
95% CI are given in parentheses.
1 HbA1c ≥7%. 2 Adjusted for gender, age, marital and employment status, education, physical activity, BMI, smoking, drinking, duration of diabetes, 
and type of diabetes treatment. 
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lems with glycemic control at t 1 . The association of med-
ication adherence and health behavior (t 0 ) on glycemic 
control at t 1 was additionally tested for the subsample of 
insulin-treated diabetics. Again, there are no significant 
associations between problems with medication adher-
ence (OR: 1.31; CI: 0.86–1.98; p = 0.210) and health be-
havior (OR: 0.99; CI: 0.91–1.08; p = 0.844) at t 0 and prob-
lems with glycemic control at t 1 .
 Discussion 
 As depressive symptoms occur frequently in patients 
with type 2 diabetes, it is important to understand how 
depression affects the treatment of diabetes. Therefore, 
we analyzed a large sample to assess prospective associa-
tions between depression, adherence, and glycemic con-
trol in patients with type 2 diabetes. 
 This study showed that depression, but not subthresh-
old depression, is prospectively associated with higher 
HbA 1c levels over a 12-month follow-up. To our knowl-
edge, this is the first study using a nationally representa-
tive cohort of adults in primary health care systems that 
showed a prospective relationship between depression 
and glycemic control.
 It is still uncertain from current research whether co-
existing depression affects glycemic control. Our study 
found that for patients with type 2 diabetes and co-exist-
ing depression at baseline, the odds of HbA 1c  6 7% versus 
HbA 1c  ! 7% at follow-up were doubled, even when various 
other factors were controlled. This study thus confirmed 
existing findings from studies using cross-sectional de-
signs indicating that depression is related to glycemic 
control  [23] . In accordance with prior research  [24] , there 
was no prospective relationship between subthreshold 
depression and both medication adherence and HbA 1c 
levels. As shown by Fisher et al.  [25] , subthreshold or non-
clinical levels of depression are more strongly correlated 
with sources of distress resulting from diabetes specifi-
cally, such as diabetes-related health care and economic, 
social, and family difficulties  [25] , than with clinical de-
pression. This could be a possible reason for the lack of 
associations between subthreshold depression and HbA 1c 
levels.
 Depression at baseline predicts more problems with 
medication adherence and health behavior at follow-up 
among patients with type 2 diabetes. According to Cra-
mer  [26] , medication adherence is defined as ‘the extent 
to which a patient acts in accordance with the prescribed 
interval and dose of a dosing regimen’, whereas medica-
tion persistence is defined as ‘the duration of time from 
initiation to discontinuation of therapy’. Our findings re-
garding adherence to medication and health behavior are 
consistent with previous cross-sectional research  [23, 27] . 
Additionally, earlier research has shown that even sub-
clinical levels of depression are associated with nonad-
herence  [10] , although again only cross-sectionally. Our 
study thus confirms these findings through a prospective 
study design, which indicates that even low levels of de-
pressive symptomatology represent a major prognostic 
risk factor for poor medication adherence and poor health 
behavior.
 Adherence to self-care behavior – like medication in-
take, dietary guidelines, or exercise – is crucial in the 
treatment of diabetes and appears to be an important 
contributor to glycemic control  [27] . Inconsistent with 
these findings, adherence to medication and health be-
havior at baseline did not predict problems with glycemic 
control (HbA 1c level  6 7%). This may be a function of dif-
ferent or imprecise methodology for measuring adher-
ence (e.g. single-item measurement of medication adher-
ence), differences in the complexity of self-care regi-
ments, different study designs, and social desirability or 
recall biases. In addition, our data show that there are low 
baseline values for medication adherence as well as health 
behavior, which might result from sample-specific char-
acteristics such as older age and long duration and treat-
ment of diabetes. Being treated for diabetes for several 
years might have improved medication adherence, and, 
with older age, the subjective standard for health behav-
ior might decrease. Thus, the variable probably did not 
provide enough variance in its distribution. It is also pos-
sible that adherence and health behavior improved over 
the course of the year, e.g. due to interventions of the re-
sponsible physician. Furthermore, previous research has 
shown that the strongest associations between adherence 
and glycemic control exist in insulin-treated diabetic pa-
tients  [28] , and focusing on this subsample may have re-
vealed a stronger relationship. Testing this hypothesis did 
not show any significant results, however, probably be-
cause the proportion of subjects with insulin treatment 
was comparatively low  [23] in our patients. 
 Several limitations relevant to interpreting the find-
ings have to be mentioned. One limitation was the use of 
self-report data on medication adherence and health be-
havior, because of a resulting tendency to overestimate 
adherence due to recall biases and social desirability. 
However, a meta-analysis comparing self-report mea-
sures with more objective methods such as electronic 
monitoring showed that self-report measurements have 
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sufficient validity and reliability  [29] . In addition, elec-
tronic monitoring is associated with high costs and there-
fore not appropriate in large-scale studies. Second, mea-
suring medication adherence with a single item repre-
sents another limitation of the study. Yet there are some 
indications that single-item measurement has sufficient 
predictive value and concordance with scales including 
multiple items to measure adherence  [30] . Third, we did 
not have any measurements for diabetes-specific self-
care, such as self-monitoring of blood glucose, foot care 
or dietary habits. This was due to the study design, in 
which data for several chronic diseases were collected, 
which prevented the use of diabetes-specific instruments. 
Moreover, there was no data on the course or treatment 
of depression during the 12-month follow-up period. 
However, depression has been shown to be persistent in 
nearly three quarters of diabetic adults at 6-month fol-
low-up  [31] , which is consistent with our data where de-
pression was persistent over the 12-month follow-up pe-
riod in half of the patients. Because depression among 
primary care patients with diabetes is predominantly un-
recognized and untreated, the findings probably would 
be similar even when treatment was accounted for. Dur-
ing a 12-month period, less than half of the patients with 
depression were recognized, less than half of them re-
ceived antidepressant descriptions, and only about 7% re-
ceived adequate psychotherapeutic treatment  [32] . By 
comparison, in our sample merely one third of the de-
pressed patients were recognized as depressed by their 
physicians, and therefore the rate of depression-related 
treatment is presumed to be correspondingly low. Mea-
suring depression with the DSQ may have resulted in an 
overestimation of depressive symptoms because diabetes 
and other medical comorbidities in primary care fre-
quently involve somatic symptoms that were probably at-
tributed to depression. However, the 11.8% rate of major 
depression found in this sample is even lower than the 
overall prevalence of depression in patients with diabetes 
of 17.6% found in a prior meta-analysis  [1] . Nevertheless, 
cross-validation in diabetic patients with a well-validated 
screening instrument for depression for the use in pri-
mary care settings may additionally be required.
 This study has several major strengths. First, the stud-
ied sample constituted a large nationally representative 
cohort of adults in primary health care. Therefore, the 
generalizability of the results to countries providing sim-
ilar health care services is very high. Second, its prospec-
tive study design enables causal inferences regarding 
HbA 1c levels and depression. Third, the study combined 
multiple data perspectives resulting in a broad frame-
work; self-reports, data collected from the physician, and 
the availability of laboratory data HbA 1c provided a large 
number of diabetes-related variables. 
 In conclusion, the results of this study of adults with 
type 2 diabetes show that there is a significant prospec-
tive relationship between depression and glycemic con-
trol, indexed by HbA 1c , and that even subthreshold de-
pression is associated to problems with adherence to 
treatment recommendations over a 12-month follow-up. 
These data clearly emphasize the importance of depres-
sion in the treatment of adults with type 2 diabetes.
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